1st August 2019


Neuro-Bio has recently appointed two new additions to our board, Mr Nick Stephens and Dr Eddy Littler.

We are extremely grateful to our current Chairman, Lord James Arbuthnot and Non-Executive Director, Dominique Kleyn for their dedication, loyalty, skill and commitment; the company will miss their good humour and sense, but we are fortunate that someone with Eddy and Nick’s experience and ability are able to take their places.

Dr Eddy Littler was COO at ReViral, a UK-based biotechnology company developing therapies for respiratory syncytial virus by developing novel first-in-class medicines. In 2018 Eddy led the fundraising of $55million Series B investment for ReViral.

Before this, he was CEO at Domainex where his main focus was on investor relations, generation and delivery of the business plan and building strategic alliances; he also led a fundraising round of $5m in 2008. He has also held senior positions in Medivir, GlaxoWellcome and Wellcome Research Laboratories and has been responsible for the development of several key medicines to patients including Simeprivir for hepatitis C virus.

Eddy Littler comments: ‘I am both excited and honoured to become the chairman of Neuro-Bio. The company has identified a novel and cutting-edge approach to both diagnose and treat people with Alzheimer’s disease, which will provide much-needed treatment of this area of high unmet clinical need. I want to thank my predecessor Lord Arbuthnot for his sterling work in helping to steer the company through its early stages, and I am looking forward to helping the company in its next phase of progress and growth built upon those strong foundations.

Baroness Greenfield adds ‘Dr Littler will bring invaluable knowledge and experience to our rapidly advancing programmes on both biomarker and drug discovery. Our disruptive approach is starting to take off and Eddy has come at just the right time to ensure we move at pace. We are confident that as Chairman, he will provide the leadership the Company will need as it moves into its next exciting phase of development.’

Mr Nick Stephens is Executive Chair of The RSA Group, a global leader in Life Sciences Executive Search and Executive Interims. Serving biotech, pharma, medical devices, diagnostic, and academic medical research markets.

He has been a Director of The RSA Group since 1986, joined the business full-time in 1995 and took the helm in 2000. Nick also serves as an Independent Non-Executive Director of an investment company focusing on cannabinoid and Internet-of-Things businesses; an early stage biotech company with a proprietary platform in oncology, anti-infectives and diagnostics, an IT business specializing in healthcare, travel and cybersecurity and an advanced AgriTech business.

Nick Stephens comments ‘Alzheimer’s is a terrifying condition that has touched most of our lives. Today it is a disease with no effective treatment. Attempts to find new cures involving Amyloid and TAU have, so far, failed to deliver. So, when the opportunity to join the Neuro-Bio Board was presented to me, I jumped at it. I’m excited to join the Neuro-Bio team and a venture that I believe may offer new hope to patients and their loved ones.’

Baroness Greenfield adds ‘having known Nick previously I am convinced he will be a very valuable addition to our team, not only because of his highly relevant biotech expertise but also, he is a highly energetic and motivated individual who will provide new insights into our Board discussions’.